Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation.
OBJECTIVE
Activating Flt3 mutations are observed in about 30% of patients with acute myeloid leukaemia (AML) and individual Flt3 mutations are applicable for minimal residual disease (MRD) analyses.


METHODS
We investigated the MRD status in four AML patients carrying different Flt3 mutations (three patients with Flt3 length mutations of the juxtamembrane domain, one patient carrying a mutation of the Flt3 tyrosine kinase domain, i.e. Flt3-TKD mutation) who underwent allogeneic peripheral blood stem cell transplantation (PBSCT). Residual leukaemia cells were retrospectively determined by real-time PCR at different time points.


RESULTS
We can demonstrate a good correlation between the course of MRD status and clinical events in all four investigated patients.


CONCLUSIONS
These examples demonstrate the potential impact of Flt3 based MRD status not only after but also prior to allogeneic PBSCT.
Scholl
Sebastian
S
Department of Internal Medicine II (Oncology and Hematology), Friedrich Schiller University, Erlanger Allee 101, 07740 Jena, Germany. sebastian.scholl@med.uni-jena.de
Loncarevic
Ivan F
IF
Krause
Claudia
C
Clement
Joachim H
JH
Höffken
Klaus
K
Sayer
Herbert G
HG
D000328:Adult; D017931:DNA Primers; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D018365:Neoplasm, Residual / Q000235:genetics* / Q000628:therapy; D016133:Polymerase Chain Reaction; D016879:Salvage Therapy; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
D017931:DNA Primers